Incretin-based drugs were not linked to HF hospitalization compared with other oral antidiabetic drug combinations | ACP Diabetes Monthly
Incretin-based drugs did not appear to be associated with greater heart failure hospitalization risk compared with commonly used combinations of oral antidiabetic drugs, a cohort study found.
Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death | ACP Diabetes Monthly
The review suggests that treating diabetes with strict glycemic control does not reduce mortality or cardiovascular risk or slow progression of kidney disease, and the results question whether strict glycemic control for preventing any complications
Metformin reduced CV events compared with glipizide in patients with type 2 diabetes and CAD | ACP Diabetes Monthly
A multicenter randomized controlled trial of Chinese patients with type 2 diabetes and coronary artery disease found that metformin reduced cardiovascular events more than glipizide at 5 years.
Review: In diabetes, benefits of lowering BP depend on baseline BP being 140 mm Hg or more | ACP Diabetes Monthly
Hypertension treatment reduced mortality and myocardial infarction in diabetic patients with a systolic blood pressure of at least 140 mm Hg, a systematic review and meta-analysis found. However, in patients with lower baseline blood pressure (BP),
Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulfonylureas increases hypoglycemia | ACP Diabetes Monthly
Adding dipeptidyl peptidase-4 (DPP-4) inhibitors to sulfonylureas was associated with 1 excess case of hypoglycemia for every 17 patients in the first 6 months of treatment, the systematic review and meta-analysis found.
Review: Adding a DPP-4 inhibitor to an SGLT-2 inhibitor reduces genital, but not genitourinary, tract infections | ACP Diabetes Monthly
The authors of an accompanying ACP Journal Club commentary noted that although the risk for bias in the five reviewed studies was reportedly low, the results were imprecise and inconsistent, leaving little confidence in the evidence of an apparent
Review: In adults with diabetes, aspirin does not prevent CV events compared with placebo | ACP Diabetes Monthly
A review published prior to the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial found that aspirin only reduced cardiovascular events in diabetes patients with pre-existing cardiovascular disease.
In type 1 diabetes, education with either insulin pumps or daily injections did not differ for HbA1c at 2 years | ACP Diabetes Monthly
The results showed that when patients on multiple daily insulin injections received structured education, there was no additional benefit of switching to pump therapy for glycemic control, hypoglycemia rates, or quality of life, according to an ACP
Two reviews analyze efficacy of newer drug classes in type 1 and type 2 diabetes | ACP Diabetes Monthly
The evidence favors glucagon-like peptide 1 agonists and, particularly, sodium–glucose cotransporter 2 inhibitors for type 2 diabetes, but the benefits in type 1 diabetes remain speculative, said an ACP Journal Club commentary.
Semaglutide reduced a composite of CV events at two years in patients with type 2 diabetes and high CV risk | ACP Diabetes Monthly
Semaglutide, a new once-weekly glucagon-like peptide-1 (GLP-1) analogue, reduced cardiovascular (CV) events compared to placebo, according to a manufacturer-sponsored study.